High-Throughput Proteomic Profiling to Evaluate Differentiation Syndrome With Menin Inhibition

Authors

Miriam B Garcia
Bofei Wang
Irtiza Sheikh
Georgina El Hajjar
David McCall
Cesar Nunez
Amber Gibson
Philip L Lorenzi
Ghayas C Issa
Branko Cuglievan
Hussein A Abbas

Language

English

Publication Date

1-30-2026

Journal

Molecular & Cellular Proteomics

DOI

10.1016/j.mcpro.2026.101522

PMID

41621809

Abstract

High-throughput proteomic profiling provides a comprehensive analysis of systemic cancer effects and tumor microenvironment interactions. Characterizing soluble proteins driving inflammation in acute myeloid leukemia (AML) offers insight into inflammatory diseases like differentiation syndrome (DS) related to AML therapies like menin inhibitors. We present our application of NUcleic acid-Linked Immuno-Sandwich Assay (NULISA), a novel technology leveraging next-generation sequencing (NGS) for high-throughput, ultra-sensitive characterization of secreted inflammatory proteins in plasma or serum. Here we report its use to identify dynamic soluble protein changes during treatment and at the time of suspected DS in pediatric AML patients treated with the menin inhibitor revumenib (NCT04065399, NCT05360160).

Keywords

acute myeloid leukemia, differentiation syndrome, menin inhibitors, pediatric, proteomics, relapsed refractory AML

Published Open-Access

yes

Recommended Citation

Garcia, Miriam B; Wang, Bofei; Sheikh, Irtiza; et al., "High-Throughput Proteomic Profiling to Evaluate Differentiation Syndrome With Menin Inhibition" (2026). Faculty, Staff and Student Publications. 5234.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/5234